ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

 

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disease for shorter periods of time. The data, presented at the 7th Joint Meeting of the ECTRIMS-ACTRIMS in Paris, also showed that opicinumab, a first-in-class monoclonal antibody directed against LINGO-1, may be beneficial in patients whose MRI results show certain brain features that suggest repair of MS lesions may be possible through remyelination. Based on the SYNERGY findings, the company also initiated its Phase 2 clinical trial AFFINITY to evaluate opicinumab as an investigational add-on therapy in people with relapsing MS. The primary endpoint of the study, Overall Response Score (ORS), is an integrated measure of both the improvement and worsening of disability over time.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC